Trump, 74, is at an increased risk for a more serious case of COVID-19 because of his age, weight, and sex.

In a memo released Friday, White House physician Sean Conley said Trump has received an injection of eight grams of Regeneron’s antibody drug. The New York biotech started clinical trials on June 11 for the experimental treatment, called REGN-COV2.

The physician’s statement noted Trump “remains fatigued but is in good spirits.” Conley also noted the president has also been taking zinc, vitamin D, famotidine, melatonin, and a daily aspirin.

Regeneron’s drug is an experimental treatment still in clinical trials. On September 29, the company released a deion of early results from the first 275 volunteers in the non-hospitalized patient study.

Chief Scientific Officer George Yancopoulos said the data confirmed the company’s belief that the drugis most likely to benefit people who did not mount an immune response before taking the drug. But trials are still ongoing, as the early results are notconclusive proof of efficacy.

What’s been working totreat COVID-19

Since the start of the coronavirus pandemic, we’ve learned a lot about how to treat COVID-19, the disease caused by the novel coronavirus.

The Food and Drug Administration has given emergency use authorization to two coronavirus treatments: the antiviral remdesivir, and convalescent plasma, or blood infusions from recovered patients.

Others, including the steroid dexamethasone, have shown promise in patients with acute infections.

Treatments created to specifically fight the novel coronavirus including the antibody treatment Trump received have shown some promise in early studies, but none are yet approved by regulators in the US for wide use.

Some treatments haven’t proven useful, including hydroxychloroquine

We’ve also learned more about what’s less effective at treating COVID-19.

Throughout March and April, Trump consistently touted the prospects of hydroxychloroquine by name.

Early studies from France and China encouraged many doctors, as well as Trump, by appearing to show promising signs that the drug may work. The FDA issued an emergency approval to treat hospitalized patients in late-March. A top-ranking government official later claimed there was political pressure put on the agency to greenlight the drug.

These initial findings were severely flawed by the limitations of the studies. The trials enrolled tiny groups of patients or lacked a control group to compare the results against. Studies that enrolled more people and tested the pills against a placebo group consistently found no benefit for hydroxychloroquine.

These negative trial results, which have been published in top peer-reviewed medical journals, found hydroxychloroquine didn’t prevent COVID-19 in people exposed to the virus, nor did it help hospitalized patients recover faster.

In June, the FDA revoked the emergency use authorization for hydroxychloroquine and chloroquine. In its statement explaining the reversal, the FDA noted serious heart-related side effects the treatment can cause. The agency concluded those risks do not outweigh any potential benefits in treating COVID-19.

10月4日周日 | 互联网医院专题讲座

互联网医院作为医院服务拓展，如何利用可穿戴设备形成互联网医疗闭环？如何让患者获益同时，保护隐私和数据安全？如何利用RPM实现人群健康指导？

本讲座适合互联网医疗人士；可穿戴设备研发人员；欢迎远程医疗人士参加。

报名微信：rongfen824/限20位；Zoom视频讲座， 付费300元/人